Aesthetic Management Partners LLC v. HydraFacial LLC

Aesthetic Management Partners LLC (AMP), the petitioner, is a provider of medical aesthetic products and practice support services, specializing in regenerative solutions for skin and hair treatments, including aesthetic energy-based devices. The company was founded in 2018 by industry veterans. HydraFacial LLC, the patent owner, is a prominent brand within the beauty health sector, operating under its parent company, The Beauty Health Company (NASDAQ: SKIN). HydraFacial is a leading manufacturer known for pioneering hydradermabrasion technology with its patented Vortex-Fusion® systems, which provide a non-invasive, three-step skin treatment. The sole patent at issue in this Inter Partes Review (IPR) is U.S. Patent No. 9,550,052, titled "Console system for the treatment of skin," which generally describes a skin treatment apparatus including a console, a handpiece, and a manifold system capable of delivering fluids from multiple sources to the handpiece.

The IPR was filed on July 3, 2025, at the Patent Trial and Appeal Board (PTAB) and has been instituted, meaning the PTAB found a reasonable likelihood that AMP would prevail on at least one challenged claim. This IPR is a defensive maneuver by AMP in response to an ongoing patent infringement lawsuit initiated by HydraFacial LLC. On July 8, 2024, HydraFacial sued Aesthetic Management Partners in the U.S. District Court for the Western District of Tennessee (Case No. 2:24-cv-02480), alleging infringement of U.S. Patent No. 9,550,052 and other patents by AMP's hydrodermabrasion systems. The district court case is currently stayed pending the outcome of a related International Trade Commission (ITC) investigation (337-TA-1416) involving the same parties and technology.

This case is notable due to the intense competition within the lucrative medical aesthetics and hydrodermabrasion market, where HydraFacial is a market leader with a history of aggressive patent enforcement. The simultaneous multi-venue litigation strategy employed by HydraFacial—pursuing infringement in both district court and the ITC while defending its patent at the PTAB—underscores the high stakes involved in protecting market share in this growing industry. The institution of the IPR is particularly significant given the PTAB's increased scrutiny and tendency toward discretionary denials based on factors like parallel district court litigation, though the IPR was filed and instituted before the USPTO Director assumed full personal control over institution decisions in October 2025.

This IPR case (IPR2025-01169) is closely related to an ongoing district court litigation and other PTAB proceedings.

Key Legal Developments and Outcome:

1. Related District Court Litigation - Filing & Initial Pleadings:

• 2024-07-08: HydraFacial LLC filed a patent infringement complaint against Aesthetic Management Partners, LLC and Aesthetic Management Partners, Inc. in the U.S. District Court for the Western District of Tennessee, Case No. 2:24-cv-02480 (the "AMP Case"). The complaint alleged infringement of five of HydraFacial's patents related to hydrodermabrasion systems, including U.S. Patent No. 9,550,052.
• Status of AMP Case: The AMP Case was stayed due to a pending International Trade Commission (ITC) investigation (ITC Sinclair Matter). HydraFacial plans to reopen the AMP Case to seek monetary damages after the conclusion of the ITC Sinclair Matter.

2. Parallel PTAB IPR Proceedings - Filing & Institution:

• 2025-07-03: Aesthetic Management Partners LLC filed the IPR petition, IPR2025-01169, challenging U.S. Patent No. 9,550,052, owned by HydraFacial LLC.
• 2026-01-16: The PTAB issued a Notice granting institution of IPR2025-01169. However, the IPR was stayed due to a pending Director Review of the institution decision in a related IPR, IPR2025-00145.

3. Director Review and Stay:

• 2026-05-01: USPTO Director John A. Squires issued an Order Initiating Sua Sponte Director Review for IPR2025-01169 (and IPR2025-01217, another IPR related to a HydraFacial patent).
• The Director's review was initiated because on February 12, 2026, the Director had vacated the Board's decision to institute IPR2025-00145. In that case, the U.S. International Trade Commission (ITC) had already found that the same challenged patent was not invalid based on the same prior art.
• The Director's order requested both parties in IPR2025-01169 to file an additional brief (no more than ten pages by May 8, 2026) addressing whether the challenged claims and asserted prior art in IPR2025-01169 are so closely related to those in IPR2025-00145 that maintaining the IPR would lead to significant duplication of effort, additional expense, and a risk of inconsistent decisions.

4. Strategic Significance of IPR and Director Review:

• The Director's actions reflect a broader policy of scrutinizing IPRs that overlap with prior litigation or have already been addressed by other forums, such as the ITC or district courts. The Director aims for AIA reviews to serve as a "true alternative to litigation," not a means to re-litigate validity after adverse outcomes in other forums.

5. Present Posture:

• The IPR2025-01169 is currently "Pending - Instituted" but is subject to Director Review, which may lead to its de-institution and termination based on the ITC's prior findings in a related matter.
• The underlying district court case, HydraFacial LLC v. Aesthetic Management Partners, LLC et al, Case No. 2:24-cv-02480, had its stay lifted on April 18, 2025, but was likely re-stayed or subject to the ongoing ITC matter, as HydraFacial stated its intent to reopen it after the ITC Sinclair Matter concludes.

This IPR is a significant part of a broader intellectual property dispute between Aesthetic Management Partners and HydraFacial, which includes district court litigation and ITC proceedings. The Director's review introduces a critical discretionary element that could significantly impact the IPR's outcome.

I am unable to definitively identify the counsel of record representing Aesthetic Management Partners LLC, the petitioner, in IPR2025-01169 based on the public web searches conducted. While related IPRs involving Aesthetic Management Partners (e.g., IPR2025-00189) and district court cases naming them as a defendant have been found, specific counsel for Aesthetic Management Partners LLC as the petitioner in IPR2025-01169 could not be sourced.

The definitive source for this information would be the official Patent Trial and Appeal Board (PTAB) docket for IPR2025-01169, which typically lists appearing counsel in the petition document or subsequent filings. Publicly accessible PTAB dockets allow for searching by case number to identify counsel of record for all parties.

General information regarding PTAB practice indicates that petitioners must designate a lead counsel and at least one back-up counsel, with lead counsel being a registered practitioner. While attorneys like Andrew P. Zappia of Troutman Pepper, located in Washington, D.C. and Rochester, are known for extensive IPR practice representing both petitioners and patent owners in various technology areas, his direct involvement in IPR2025-01169 for Aesthetic Management Partners LLC was not confirmed.

HydraFacial LLC, the defendant in IPR2025-01169, is represented by attorneys from Morgan, Lewis & Bockius LLP. The following counsel are of record for HydraFacial LLC:

• Ali S. Razai

  • Role: Partner, Lead Counsel.
  • Firm: Morgan, Lewis & Bockius LLP, Orange County, California office.
  • Experience: Mr. Razai is a first-chair litigator specializing in high-stakes intellectual property disputes, including patents, trademarks, and trade secrets. He represents companies in various sectors, including biotechnology, medical device, and pharmaceutical industries, before federal district courts, federal appellate courts, the International Trade Commission (ITC), and the Patent Trial and Appeal Board (PTAB). He was part of a Morgan Lewis team that secured a favorable jury verdict for Lululemon in a patent dispute with Nike and also received "shout-out" honors for fending off Nike's patent assertions against Lululemon.

• Benjamin J. Everton

  • Role: Partner.
  • Firm: Morgan, Lewis & Bockius LLP, Orange County, California office.
  • Experience: Mr. Everton focuses on intellectual property disputes involving patents, trademarks, trade secrets, and technology before federal district courts, the ITC, and the PTAB. He has extensive experience representing both patent owners and petitioners in inter partes review (IPR) proceedings and has obtained favorable patent validity decisions for medical device and healthcare companies in IPRs. His background is in mechanical engineering. He was also part of the Morgan Lewis team recognized for successfully defending Lululemon against Nike's patent claims.

• Benjamin B. Anger

  • Role: Partner.
  • Firm: Morgan, Lewis & Bockius LLP, Orange County, California office.
  • Experience: Mr. Anger is an intellectual property litigator handling utility patents, design patents, trademarks, trade dress, and unfair competition cases. He counsels clients in life sciences, chemistry, medical device, and consumer products industries. His experience includes successfully challenging patent validity in IPRs before the PTAB and obtaining summary judgment of noninfringement for medical device companies. He has a chemical engineering background.

• Alexander B. Stein

  • Role: Partner.
  • Firm: Morgan, Lewis & Bockius LLP, Seattle, Washington office (also noted in Palo Alto/Silicon Valley).
  • Experience: Mr. Stein leads the firm's patent practice in Seattle and co-leads the firm's USPTO Patent Trial and Appeal Board (PTAB) litigation practice, focusing on PTAB strategies. He oversees more than 80 America Invents Act (AIA) trial proceedings and has helped clients obtain hundreds of domestic and international patents. His background is in software engineering, with prior experience in the medical device industry. He has co-authored articles on key developments affecting USPTO proceedings.

• Jacob L. Peterson

  • Role: Partner.
  • Firm: Morgan, Lewis & Bockius LLP, Orange County, California office (also noted in Seattle).
  • Experience: Mr. Peterson represents clients in intellectual property disputes with a focus on patent matters before federal courts, the Patent Trial and Appeal Board, and the US International Trade Commission. He advises clients in various industries, including consumer products, medical devices, and robotics. He successfully defended the validity of patents owned by a medical device company before the PTAB. He was also part of the Morgan Lewis team that received "shout-out" honors for their work on the Lululemon v. Nike patent dispute.